Loading
IBI354 is an experimental antibody-drug conjugate from Innovent Biologics (Suzhou) in phase 3 trials for HER2-positive breast cancer and ovarian cancer, aimed at HER2.
IBI354 is an antibody-drug conjugate developed by Innovent Biologics (Suzhou) and Innovent Biopharmaceutical Technology (Hangzhou). Its target is HER2 (the sponsor names HER2). The sponsor states: IBI354 is a HER2-targeting antibody-drug conjugate (ADC), given as a 12 mg/kg IV infusion every three weeks, studied versus investigator's choice of chemotherapy in HER2-expressing tumours. ClinicalTrials.gov describes the intervention as: Recombinant Anti-HER2 monoclonal Antibody-Camptothecin derivative conjugate for injection. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07377643 (IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer) and NCT06834672 (Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer), in HER2-positive breast cancer and ovarian cancer. The largest, NCT07377643, plans to enrol 540 participants with primary completion expected 2028-04-28. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
IBI354 is a HER2-targeting antibody-drug conjugate (ADC), given as a 12 mg/kg IV infusion every three weeks, studied versus investigator's choice of chemotherapy in HER2-expressing tumours. Connects to HER2.
1.IBI354's antibody arm binds HER2 on the surface of the cancer cell.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"IBI354" OR ABSTRACT:"IBI354") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IBI354, not a curated reading list.
Shares HER2, HER2-positive breast cancer and the tag pipeline.
Shares Innovent Biologics and the tag pipeline.
Shares Innovent Biologics and the tag pipeline.
Shares HER2, HER2-positive breast cancer and the tag pipeline.
Shares Innovent Biologics and the tag pipeline.
Shares HER2, HER2-positive breast cancer and the tag pipeline.
Shares HER2, HER2-positive breast cancer and the tag pipeline.
Shares HER2, HER2-positive breast cancer and the tag pipeline.